BY MARIA OUTZE NIELSEN
-
Novo Nordisk chief “relieved” after approval of Catalent takeover
The authorization from global authorities of Novo Holdings’ procurement of Catalent was anticipated, claims Lars Fruergaard Jørgensen.
-
GSK’s cancer drug combination shown to reduce risk of death
New information reveals that GSK’s Blenrep in mix with various other cancer cells therapies decreases the threat of fatality in individuals with blood cancers cells by 42%.
-
Nobel laureate: Novo Nordisk’s success is also a risk for Denmark’s economy
” To wager whatever or a great deal on one huge business is truthfully– traditionally talking– throwing down the gauntlet,” states freshly assigned Nobel la…
-
Bioage Labs stops phase 2 trial of weight-loss drug – stock drops 76%
US-based Bioage Labs’ lead medicine prospect, azelaprag, for the therapy of weight problems has a possibly hazardous negative effects.
-
GSK’s cancer drug combination shown to reduce risk of death
New data shows that GSK’s Blenrep in combination with other cancer treatments reduces the risk of death in people with blood cancers by 42%.
-
GSK will complete new Alzheimer’s project with Muna Therapeutics within five years after “massive infusion”
The Danish biotech business is backed by moneying from a brand-new cooperation with GSK to locate a therapy for Alzheimer’s condition.
-
Killing of US health insurer’s chief exec is a “huge wake-up call”
There are numerous instances of pharmaceutical business Chief executive officers being endangered and bothered over the last few years, according to Endpoints.
-
Novo’s biggest investment in quality control to move hundreds of jobs to new Danish lab
A brand-new significant lab will certainly enhance the quality assurance of Novo Nordisk’s medications. Novo SVP rejects that the development is because of obstacles with the…
-
Danish biotech company raises serious capital to develop new obesity drug
With brand-new financier assistance, Antag Rehabs can send out a brand-new weight problems prospect right into the scientific stage. According to the business’s chief executi…
-
Novo Nordisk director resigns from major board position
Camilla Sylvest, executive vice head of state of Novo Nordisk, leaves the board of meat provider Danish Crown.
